Fluvoxamine Extended-Release Capsules and Naloxegol

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.

Coadministration with inhibitors of P-glycoprotein (P-gp) and/or weak inhibitors of CYP450 3A4 may increase the plasma concentrations of naloxegol, which is a substrate of both the efflux transporter and the isoenzyme. When a single 25 mg dose of naloxegol was administered with a single 600 mg dose of quinidine, a potent P-gp inhibitor and weak CYP450 3A4 inhibitor, naloxegol peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 147% and 39%, respectively. These changes are not considered clinically significant; therefore, no dosage adjustments are necessary.

Fluvoxamine Extended-Release Capsules

Generic Name: fluvoxamine

Brand name: Luvox, Luvox CR

Synonyms: Fluvoxamine

What is Fluvoxamine Extended-Release Capsules?

Naloxegol

Generic Name: naloxegol

Brand name: Movantik

Synonyms: n.a.

What is Naloxegol?